Trial · NCT05253833
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
NCT05253833, Phase 2, Completed, Arthrosi Therapeutics
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout. Trials, record NCT05253833. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05253833
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
- NCT number
- NCT05253833
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 42 participants, actual
- Lead sponsor
- Arthrosi Therapeutics
- Conditions
- Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
- Interventions
- AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet
- First posted
- 2022-02-24
- Last updated
- 2025-01-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum urate (uric acid) (sUA) level < 5 mg/dL at month 3 | 12 weeks | Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \< 5 mg/dL at month 3 |
| Secondary | Change from baseline in tophus area at Months 3 and 6 | 12 weeks and 24 weeks | Comparison of the treatment groups for tophus area as measured by digital calipers |
| Secondary | Change from baseline in tophus crystal volume at Months 6 | 24 weeks | Comparison of the treatment groups for tophus crystal as measured by Dual-energy computerized tomography. |
| Secondary | Serum urate (uric acid) (sUA) level <6, <4 and <3 mg/dL at month 3 | 12 weeks | Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \<6, \<4 and \<3 mg/dL at month 3 |
| Secondary | Serum urate (uric acid) (sUA) level <6, < 5, <4 and <3 mg/dL at month 6 | 24 weeks | Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \<6, \< 5, \<4 and \<3 mg/dL at month 6 |
| Secondary | Incidence of Adverse Events | 24 weeks | Treatment Emergent Adverse Events and Serious Adverse Event incidence. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05253833
GET https://conductscience.org/api/trials/v1/NCT05253833/registered